Table 6 Hazard Event Rates Ratios for prescribing cascades
From: An examination of three prescribing cascades in a cohort of older adults with dementia
Main Analysis (Full Cohorts) | Cholinesterase Inhibitor User (n = 5772) | No Cholinesterase Inhibitor (n = 13,770) |
|---|---|---|
Total Number (%) of events (newly dispensed bladder anticholinergic) | 366 (6.3%) | 868 (6.3%) |
Duration of Follow-up, mean ± SD, days | 525 ± 75.3 | 332 ± 27.7 |
Unadjusted HR (95% CI) | 0.77 (0.68–0.87) | 1.00 (Referent) |
Adjusted HR (95% CI) (age, sex, rural/urban) | 0.79 (0.68–0.92) | 1.00 (Referent) |
Main Analysis (Full Cohorts) | CCB User (n = 4639) | No CCB (n = 14,903) |
Total Number (%) of events (newly dispensed diuretic) | 1708 (36.8%) | 4536 (30.4%) |
Duration of Follow-up, mean ± SD, days | 653.1 ± 24.6 | 651.3 ± 17.4 |
Unadjusted HR (95% CI) | 1.00 (0.94–1.05) | 1.00 (Referent) |
Adjusted HR (95% CI) (age, sex, rural/urban) | 1.04 (0.98–1.10) | 1.00 (Referent) |